Back to Journals » Clinical Ophthalmology » Volume 4

Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant

Authors Myung J, Aaker GD, Kiss S

Published 6 December 2010 Volume 2010:4 Pages 1423—1426


Review by Single-blind

Peer reviewer comments 2

Jane S Myung, Grant D Aaker, Szilárd Kiss
Department of Ophthalmology, Weill Cornell Medical Center, New York, NY, USA

Purpose: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis.
Methods: A retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7 mg intravitreal implant was performed. Complete ophthalmic examination including signs of inflammatory activity, visual acuity, fundus photography, fluorescein angiography, optical coherence tomography, and tolerability of the implant were assessed.
Results: Six eyes of 4 consecutive patients treated with a total of 8 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Two patients presented with unilateral idiopathic posterior uveitis; 2 patients had bilateral posterior uveitis, one secondary to sarcoidosis and the other to Vogt-Koyanagi-Harada syndrome. All eyes showed clinical and angiographic evidence of decreased inflammation following implant placement. Mean follow-up time post-injection was 5.25 months. Four eyes received 1 and 2 eyes received 2 Ozurdex implants during the follow-up period. The duration of effect of the implant was 3 to 4 months. No serious ocular or systemic adverse events were noted during the follow-up period.
Conclusions: In patients with noninfectious posterior uveitis, sustained-release dexamethasone 0.7 mg intravitreal implant may be an effective treatment option for controlling intraocular inflammation.

Keywords: corticosteroids, dexamethasone implant, Ozurdex, uveitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Pachychoroid neovasculopathy in extramacular choroidal neovascularization

Gupta MP, Rusu I, Seidman C, Orlin A, D'Amico DJ, Kiss S

Clinical Ophthalmology 2016, 10:1275-1282

Published Date: 12 July 2016

Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema

Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, Kowalski JW

Clinical Ophthalmology 2014, 8:1611-1621

Published Date: 26 August 2014

Boston type I keratoprosthesis-donor cornea interface evaluated by high-definition spectral-domain anterior segment optical coherence tomography

Alzaga Fernandez AG, Radcliffe NM, Sippel KC, Rosenblatt MI, Sood P, Starr CE, Ciralsky JB, D'Amico DJ, Kiss S

Clinical Ophthalmology 2012, 6:1355-1359

Published Date: 27 August 2012

Optical coherence tomography predicts visual outcome in macula-involving rhegmatogenous retinal detachment

Cho M, Witmer MT, Favarone G, Chan RVP, D'Amico DJ, Kiss S

Clinical Ophthalmology 2012, 6:91-96

Published Date: 11 January 2012

Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography

Grant D Aaker, Jane S Myung, Joshua R Ehrlich, et all

Clinical Ophthalmology 2010, 4:1427-1432

Published Date: 6 December 2010

Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography

Aziz A Khanifar, George J Parlitsis, Joshua R Ehrlich, et al

Clinical Ophthalmology 2010, 4:1007-1013

Published Date: 14 September 2010

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010